

# LSI Medience Corporation

## **LSI Medience Joins the Global Diagnostics Network (GDN)**

*The GDN, powered by U.S.-based Quest Diagnostics, brings together leaders in diagnostics information services to share expertise and drive innovation*

July 19<sup>th</sup>, 2019 – LSI Medience Corporation announced today that it has joined the Global Diagnostics Network (GDN), a strategic working group of major diagnostic laboratories collaborating to generate enhanced diagnostics insights to improve the delivery of global healthcare. The GDN, launched in October 2018 by U.S.-based Quest Diagnostics, also consists of the following companies: Al Borg Medical Laboratories, Dasa, GC Labs, KingMed Diagnostics, Healius, SYNLAB. Additionally LSIM and Strand Life Sciences join the GDN today. Collectively, this worldwide community of nine leading healthcare companies has a presence in countries with two-thirds of the world's population, and over 90% of the global pharmaceutical market.

GDN initiatives will benefit patients, healthcare providers, pharmaceutical innovators, government agencies, non-governmental organizations (NGOs), and academic institutions. Starting priority areas of focus include the standardized delivery and development of high quality companion diagnostics for pharmaceutical companies, and the creation of an emerging pathogen preparedness network to expedite infectious disease research and response. Additional initiatives will be rolled out based on regional and global priorities.

“It is our great pleasure for our Clinical Laboratory Business Segment to participate in this global network of diagnostic excellence consisting of leading healthcare companies in each region,” said Haruo Watanabe, President and CEO of LSI Medience Corporation. “GDN initiatives have their sights set on global cooperation. We expect to contribute not only to provision of healthcare services, mainly based on clinical testing, established in one of the most aging societies in the world to GDN members, but also to global healthcare through collaboration with the members to enable advanced and diverse diagnostic technologies.”

“We welcome these two new GDN members and are eager to continue acceleration of the network's programs that will reach patients in every part of the world,” said Mark Machulcz, Managing Director of Global Markets at Quest Diagnostics. “Since launching in October 2018, the GDN has made great strides in increasing access to diagnostic technology innovation, and in building the largest global launch platform for rapid deployment of companion diagnostics.

### [About Quest Diagnostics]

Quest Diagnostics empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management.

Quest annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our 46,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives.

[www.QuestDiagnostics.com](http://www.QuestDiagnostics.com).

Quest, Quest Diagnostics, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks are the property of their respective owners.

# LSI Medience Corporation

## [About LSI Medience Corporation]

Founded in 1975, LSI Medience Corporation is engaged in clinical testing, diagnostics reagents and instruments, and drug development support service as its three core businesses. By utilizing its power of analysis developed in various testing fields in its long history as a core competence and analytical abilities on test results as well, LSI Medience Corporation aims to create new solutions. Contributing to prevention and early detection of diseases and medical care, it also actively supports next-generation healthcare including personalized medicine. LSI Medience is one of the comprehensive leading healthcare service companies in Japan with 89.4 billion yen net sales in FY2017 and approximately 3,500 employees (as of March 31, 2018). For further information, please visit

[www.medience.co.jp/english/](http://www.medience.co.jp/english/)

## [About the Global Diagnostics Network]

The Global Diagnostics Network (GDN) is a strategic working group of diagnostic laboratories across major regions, each committed to unleashing and sharing local innovation to increase global access to diagnostic science, information, and services.

The GDN enables sharing of best practices among the top scientific minds internationally, which will accelerate the development and delivery of advanced diagnostics and ultimately generate enhanced diagnostic insights to improve the delivery of global healthcare. GDN initiatives benefit patients, healthcare providers, referring practitioners, pharmaceutical innovators, government agencies, non-governmental organizations (NGOs), and academic institutions.

For more information about the GDN, please visit [www.globaldiagnosticsnetwork.com](http://www.globaldiagnosticsnetwork.com)